Purpose: The aim of this study was to compare the efficacy of two contrast materials with moderate and high iodine concentrations for the depiction of pancreatic adenocarcinoma.
Materials And Methods: A series of 107 patients with histologically proven pancreatic adenocarcinoma underwent helical computed tomography. A fixed dose of 100 ml of iopamidol 300 (mg I/ml) was administered to 50 patients (group A) and iopamidol 370 (mg I/ml) to 57 patients (group B) at the same injection rate (3 ml/s). Unenhanced helical scans and contrast-enhanced scans for three phases (30, 70, and 300 s after starting the infusion of contrast material) were obtained. We evaluated enhancement of the aorta, portal vein, hepatic parenchyma, pancreatic parenchyma, and pancreatic adenocarcinoma during each phase.
Results: During all phases, both aortic and pancreatic enhancement were significantly greater in group B than in group A (P<0.01). Enhancement of the portal vein and hepatic parenchyma was significantly greater at 70 and 300 s in group B than in group A (both P<0.01). Tumor-to-pancreas contrast was significantly greater in group B than in group A at both 30 s (P<0.01) and 70 s (P<0.05).
Conclusion: Administration of contrast material with a high iodine concentration is more effective for depicting pancreatic adenocarcinomas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11604-008-0240-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Review of Circulating Tumor DNA (ctDNA) in Pancreatic Cancer: Ready for the Clinic?
J Gastrointest Cancer
January 2025
Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Pancreatic ductal adenocarcinoma is a devastating disease which is associated with an increase in cancer-related death in the USA. The minority of patients are cured by surgery alone and typically require adjuvant chemotherapy in order to improve clinical outcomes. Circulating tumor DNA (ctDNA) is an emerging technology whereby microscopic levels of minimal residual disease (MRD) can be detected in the bloodstream.
View Article and Find Full Text PDFRevealing the role of cancer-associated fibroblast senescence in prognosis and immune landscape in pancreatic cancer.
iScience
January 2025
Department of Gastroenterology and Hepatology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Cancer-associated fibroblasts (CAFs) represent a major contributor to tumor growth. Cellular senescence is a state of cell-cycle arrest characterized by a pro-inflammatory phenotype. The potential impact of CAF senescence on tumor progression and the tumor microenvironment (TME) remains to be elucidated.
View Article and Find Full Text PDFRisk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis.
Ann Med
December 2025
Department of Hepatobiliary and Pancreatic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China.
Background: Numerous meta-analyses have identified various risk factors for hepatocellular carcinoma (HCC), prompting a comprehensive study to synthesize evidence quality and strength.
Methods: This umbrella review of meta-analyses was conducted throughout PubMed, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews. Evidence strength was evaluated according to the evidence categories criteria.
Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer.
Cancer Sci
January 2025
Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal disease with poor prognosis and limited treatment options. While the majority of PDAC cases harbor KRAS mutations, approximately 8%-10% are KRAS wild-type (KRAS-WT). These KRAS-WT tumors often contain actionable mutations and gene fusions, making them more suitable for precision therapies.
View Article and Find Full Text PDFStudy protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.
BMC Cancer
January 2025
Barts Cancer Institute and Wolfson Institute of Public Health, Mary University of London, John Vane Science Centre, Charterhouse Square, London, Queen, EC1M 6BQ, UK.
Background: Pancreatic cancer (PDAC: pancreatic ductal adenocarcinoma, the commonest form), a lethal disease, is best treated with surgical excision but is feasible in less than a fifth of patients. Around a third of patients presentlocally advanced, inoperable, non-metastatic (laPDAC), whose stadrd of care is palliative chemotherapy; a small minority are down-sized sufficiently to enable surgical excision. We propose a phase II clinical trial to test whether a combination of standard chemotherapy (gemcitabine & nab-Paclitaxel: GEM-NABP) and repurposing All Trans Retinoic Acid (ATRA) to target the stroma may extend progression-free survival and enable successful surgical resection for patients with laPDAC, since data from phase IB clinical trial demonstrate safety of GEM-NABP-ATRA combination to patients with advanced PDAC with potential therapeutic benefit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!